Marah C. Runtsch
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Marah C. Runtsch has a total of 94 co-authors. Here are the top co-authors by number of shared publications:
- Julia Kargl
Medical University of Graz
4 shared publications - Anna Lueger
Division of Pharmacology, Otto Loewi Research Center, Medical University of Graz, Graz, Austria
3 shared publications - Kathrin Maitz
Division of Pharmacology, Otto Loewi Research Center, Medical University of Graz, Graz, Austria
3 shared publications - Luke Anthony John O'NEill
Trinity College Dublin
2 shared publications - Adam Wahida
Institute of Metabolism and Cell Death, Helmholtz Zentrum München, Neuherberg, Germany
1 shared publication Afroditi Moulara
Cellular Immunology Laboratory, Center of Basic Research, Biomedical Research Foundation of the Academy of Athens, 115 27 Athens, Greece
1 shared publication
Latest Publications
- 26 November 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (826) , eadu3313
Lymphotoxin alpha eradicates acute myeloid leukemia and simultaneously promotes healthy hematopoiesis in mice
Acute myeloid leukemia (AML) is characterized by frequent relapse, which is driven by resistant leukemic stem or progenitor cells (LSCs). Here, we reported on a tumor-suppressive mechanism that can be harnessed to simultaneously clear LSCs and promote healthy hematopoiesis. Genetic deletion of the tumor necrosis factor (TNF) superfamily member lymphotoxin alpha ( Lta ) blocked cell death and accelerated leukemogenesis in murine AML models. Accordingly, exposure of leukemic cells to exogenous recombinant lymphotoxin alpha (LTα 3 ) induced myeloid differentiation and, in part, cell death in AML progenitors. In syngeneic and patient-derived xenograft mouse models, exposure to recombinant LTα 3 resulted in deep and durable remissions. LTα 3 repressed leukemia by depleting tumor necrosis factor receptor (TNFR)–associated factor 2 (TRAF2) through activation of TNF receptors TNFR1 and TNFR2. In contrast with conventional therapies, LTα 3 exerted only minimal toxicity on the healthy hematopoiesis but instead promoted hematopoietic progenitors. Leveraging this endogenous tumor-suppressive mechanism may decouple treatment efficacy on malignant cells from undesired bone marrow suppression.
- 26 November 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (826) , eadu3313
Lymphotoxin alpha eradicates acute myeloid leukemia and simultaneously promotes healthy hematopoiesis in mice
Acute myeloid leukemia (AML) is characterized by frequent relapse, which is driven by resistant leukemic stem or progenitor cells (LSCs). Here, we reported on a tumor-suppressive mechanism that can be harnessed to simultaneously clear LSCs and promote healthy hematopoiesis. Genetic deletion of the tumor necrosis factor (TNF) superfamily member lymphotoxin alpha ( Lta ) blocked cell death and accelerated leukemogenesis in murine AML models. Accordingly, exposure of leukemic cells to exogenous recombinant lymphotoxin alpha (LTα 3 ) induced myeloid differentiation and, in part, cell death in AML progenitors. In syngeneic and patient-derived xenograft mouse models, exposure to recombinant LTα 3 resulted in deep and durable remissions. LTα 3 repressed leukemia by depleting tumor necrosis factor receptor (TNFR)–associated factor 2 (TRAF2) through activation of TNF receptors TNFR1 and TNFR2. In contrast with conventional therapies, LTα 3 exerted only minimal toxicity on the healthy hematopoiesis but instead promoted hematopoietic progenitors. Leveraging this endogenous tumor-suppressive mechanism may decouple treatment efficacy on malignant cells from undesired bone marrow suppression.
- 23 September 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 18 (905) , eadr3177
Adenosine 2A receptor–dependent activation of AMPK represses T H 17 cell pathogenicity through epigenetic and metabolic reprogramming
Metabolic reprogramming controls protective and pathogenic T helper 17 (T H 17) cell responses. When naïve T cells are differentiated into T H 17 cells in vitro, the presence of the cytokine activin A promotes their maturation into a nonpathogenic state. Here, we found that nonpathogenic T H 17 cells induced by activin A displayed reduced aerobic glycolysis and increased oxidative phosphorylation (OXPHOS). In response to activin A, signaling through the adenosine A 2A receptor (A 2A R) and AMP-activated protein kinase (AMPK) enhanced OXPHOS and reprogrammed pathogenic T H 17 cells toward nonpathogenic states that did not induce central nervous system autoimmunity in a mouse model of multiple sclerosis. In pathogenic T H 17 cells, the transcriptional coactivator p300/CBP-associated factor (PCAF) increased acetylation at histone 3 Lys 9 (H3K9ac) of genes involved in aerobic glycolysis and T H 17 pathogenic programs. In contrast, in nonpathogenic activin A–treated T H 17 cells, AMPK signaling suppressed PCAF-mediated H3K9ac modification of genes involved in aerobic metabolism and enhanced H3K9ac modification of genes involved in OXPHOS and nonpathogenic T H 17 programs. Together, our findings uncover A 2A R-AMPK signaling as a central metabolic checkpoint that suppresses T H 17 cell pathogenicity.
- 23 September 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 18 (905) , eadr3177
Adenosine 2A receptor–dependent activation of AMPK represses T H 17 cell pathogenicity through epigenetic and metabolic reprogramming
Metabolic reprogramming controls protective and pathogenic T helper 17 (T H 17) cell responses. When naïve T cells are differentiated into T H 17 cells in vitro, the presence of the cytokine activin A promotes their maturation into a nonpathogenic state. Here, we found that nonpathogenic T H 17 cells induced by activin A displayed reduced aerobic glycolysis and increased oxidative phosphorylation (OXPHOS). In response to activin A, signaling through the adenosine A 2A receptor (A 2A R) and AMP-activated protein kinase (AMPK) enhanced OXPHOS and reprogrammed pathogenic T H 17 cells toward nonpathogenic states that did not induce central nervous system autoimmunity in a mouse model of multiple sclerosis. In pathogenic T H 17 cells, the transcriptional coactivator p300/CBP-associated factor (PCAF) increased acetylation at histone 3 Lys 9 (H3K9ac) of genes involved in aerobic glycolysis and T H 17 pathogenic programs. In contrast, in nonpathogenic activin A–treated T H 17 cells, AMPK signaling suppressed PCAF-mediated H3K9ac modification of genes involved in aerobic metabolism and enhanced H3K9ac modification of genes involved in OXPHOS and nonpathogenic T H 17 programs. Together, our findings uncover A 2A R-AMPK signaling as a central metabolic checkpoint that suppresses T H 17 cell pathogenicity.
- 4 June 2025
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 273, 108893
Targeting myeloid cell immunometabolism to improve current non-small cell lung cancer therapies
- 4 June 2025
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 273, 108893
Targeting myeloid cell immunometabolism to improve current non-small cell lung cancer therapies
- Open Access
- 24 January 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (4) , eadq7307
Mitochondrial respiratory complex III sustains IL-10 production in activated macrophages and promotes tumor-mediated immune evasion
The cytokine interleukin-10 (IL-10) limits the immune response and promotes resolution of acute inflammation. Because of its immunosuppressive effects, IL-10 up-regulation is a common feature of tumor progression and metastasis. Recently, IL-10 regulation has been shown to depend on mitochondria and redox-sensitive signals. We have found that Suppressor of site III Qo Electron Leak 1.2 (S3QEL 1.2), a specific inhibitor of reactive oxygen species (ROS) production from mitochondrial complex III, and myxothiazol, a complex III inhibitor, decrease IL-10 in lipopolysaccharide (LPS)–activated macrophages. IL-10 down-regulation is likely to be mediated by suppression of c-Fos, which is a subunit of activator protein 1 (AP1), a transcription factor required for IL-10 gene expression. S3QEL 1.2 impairs IL-10 production in vivo after LPS challenge and promotes the survival of mice bearing B16F10 melanoma by lowering tumor growth. Our data identify a link between complex III–dependent ROS generation and IL-10 production in macrophages, the targeting of which could have potential in boosting antitumor immunity.
- 24 January 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (4) , eadq7307
Open AccessMitochondrial respiratory complex III sustains IL-10 production in activated macrophages and promotes tumor-mediated immune evasion
The cytokine interleukin-10 (IL-10) limits the immune response and promotes resolution of acute inflammation. Because of its immunosuppressive effects, IL-10 up-regulation is a common feature of tumor progression and metastasis. Recently, IL-10 regulation has been shown to depend on mitochondria and redox-sensitive signals. We have found that Suppressor of site III Qo Electron Leak 1.2 (S3QEL 1.2), a specific inhibitor of reactive oxygen species (ROS) production from mitochondrial complex III, and myxothiazol, a complex III inhibitor, decrease IL-10 in lipopolysaccharide (LPS)–activated macrophages. IL-10 down-regulation is likely to be mediated by suppression of c-Fos, which is a subunit of activator protein 1 (AP1), a transcription factor required for IL-10 gene expression. S3QEL 1.2 impairs IL-10 production in vivo after LPS challenge and promotes the survival of mice bearing B16F10 melanoma by lowering tumor growth. Our data identify a link between complex III–dependent ROS generation and IL-10 production in macrophages, the targeting of which could have potential in boosting antitumor immunity.
- Open Access
- 9 August 2023
- Published by MDPI AG in Antioxidants
- Vol. 12 (8) , 1587
Myeloperoxidase Alters Lung Cancer Cell Function to Benefit Their Survival
Myeloperoxidase (MPO) is a neutrophil-derived enzyme that has been recently associated with tumour development. However, the mechanisms by which this enzyme exerts its functions remain unclear. In this study, we investigated whether myeloperoxidase can alter the function of A549 human lung cancer cells. We observed that MPO promoted the proliferation of cancer cells and inhibited their apoptosis. Additionally, it increased the phosphorylation of AKT and ERK. MPO was rapidly bound to and internalized by A549 cells, retaining its enzymatic activity. Furthermore, MPO partially translocated into the nucleus and was detected in the chromatin-enriched fraction. Effects of MPO on cancer cell function could be reduced when MPO uptake was blocked with heparin or upon inhibition of the enzymatic activity with the MPO inhibitor 4-aminobenzoic acid hydrazide (4-ABAH). Lastly, we have shown that tumour-bearing mice treated with 4-ABAH had reduced tumour burden when compared to control mice. Our results highlight the role of MPO as a neutrophil-derived enzyme that can alter the function of lung cancer cells.
- 9 August 2023
- Published by MDPI AG in Antioxidants
- Vol. 12 (8) , 1587
Open AccessMyeloperoxidase Alters Lung Cancer Cell Function to Benefit Their Survival
Myeloperoxidase (MPO) is a neutrophil-derived enzyme that has been recently associated with tumour development. However, the mechanisms by which this enzyme exerts its functions remain unclear. In this study, we investigated whether myeloperoxidase can alter the function of A549 human lung cancer cells. We observed that MPO promoted the proliferation of cancer cells and inhibited their apoptosis. Additionally, it increased the phosphorylation of AKT and ERK. MPO was rapidly bound to and internalized by A549 cells, retaining its enzymatic activity. Furthermore, MPO partially translocated into the nucleus and was detected in the chromatin-enriched fraction. Effects of MPO on cancer cell function could be reduced when MPO uptake was blocked with heparin or upon inhibition of the enzymatic activity with the MPO inhibitor 4-aminobenzoic acid hydrazide (4-ABAH). Lastly, we have shown that tumour-bearing mice treated with 4-ABAH had reduced tumour burden when compared to control mice. Our results highlight the role of MPO as a neutrophil-derived enzyme that can alter the function of lung cancer cells.
- 19 May 2023
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 201, 50
Myeloperoxidase alters T cell function and plays an immunosuppressive role in non-small cell lung cancer
- 19 May 2023
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 201, 50
Myeloperoxidase alters T cell function and plays an immunosuppressive role in non-small cell lung cancer
- Open Access
- 3 September 2020
- Published by Wiley in Journal of Neurochemistry
- Vol. 158 (1) , 36-58
Metabolic determinants of leukocyte pathogenicity in neurological diseases
Neuroinflammatory and neurodegenerative diseases are characterized by the recruitment of circulating blood‐borne innate and adaptive immune cells into the central nervous system (CNS). These leukocytes sustain the detrimental response in the CNS by releasing pro‐inflammatory mediators that induce activation of local glial cells, blood–brain barrier (BBB) dysfunction, and neural cell death. However, infiltrating peripheral immune cells could also dampen CNS inflammation and support tissue repair. Recent advances in the field of immunometabolism demonstrate the importance of metabolic reprogramming for the activation and functionality of such innate and adaptive immune cell populations. In particular, an increasing body of evidence suggests that the activity of metabolites and metabolic enzymes could influence the pathogenic potential of immune cells during neuroinflammatory and neurodegenerative disorders. In this review, we discuss the role of intracellular metabolic cues in regulating leukocyte‐mediated CNS damage in Alzheimer's and Parkinson's disease, multiple sclerosis and stroke, highlighting the therapeutic potential of drugs targeting metabolic pathways for the treatment of neurological diseases. image
- 3 September 2020
- Published by Wiley in Journal of Neurochemistry
- Vol. 158 (1) , 36-58
Open AccessMetabolic determinants of leukocyte pathogenicity in neurological diseases
Neuroinflammatory and neurodegenerative diseases are characterized by the recruitment of circulating blood‐borne innate and adaptive immune cells into the central nervous system (CNS). These leukocytes sustain the detrimental response in the CNS by releasing pro‐inflammatory mediators that induce activation of local glial cells, blood–brain barrier (BBB) dysfunction, and neural cell death. However, infiltrating peripheral immune cells could also dampen CNS inflammation and support tissue repair. Recent advances in the field of immunometabolism demonstrate the importance of metabolic reprogramming for the activation and functionality of such innate and adaptive immune cell populations. In particular, an increasing body of evidence suggests that the activity of metabolites and metabolic enzymes could influence the pathogenic potential of immune cells during neuroinflammatory and neurodegenerative disorders. In this review, we discuss the role of intracellular metabolic cues in regulating leukocyte‐mediated CNS damage in Alzheimer's and Parkinson's disease, multiple sclerosis and stroke, highlighting the therapeutic potential of drugs targeting metabolic pathways for the treatment of neurological diseases. image
- Open Access
- 15 February 2019
- Published by Public Library of Science (PLoS) in PLOS Genetics
- Vol. 15 (2) , e1007970
Anti-inflammatory microRNA-146a protects mice from diet-induced metabolic disease
Identifying regulatory mechanisms that influence inflammation in metabolic tissues is critical for developing novel metabolic disease treatments. Here, we investigated the role of microRNA-146a (miR-146a) during diet-induced obesity in mice. miR-146a is reduced in obese and type 2 diabetic patients and our results reveal that miR-146a-/- mice fed a high-fat diet (HFD) have exaggerated weight gain, increased adiposity, hepatosteatosis, and dysregulated blood glucose levels compared to wild-type controls. Pro-inflammatory genes and NF-κB activation increase in miR-146a-/- mice, indicating a role for this miRNA in regulating inflammatory pathways. RNA-sequencing of adipose tissue macrophages demonstrated a role for miR-146a in regulating both inflammation and cellular metabolism, including the mTOR pathway, during obesity. Further, we demonstrate that miR-146a regulates inflammation, cellular respiration and glycolysis in macrophages through a mechanism involving its direct target Traf6. Finally, we found that administration of rapamycin, an inhibitor of mTOR, was able to rescue the obesity phenotype in miR-146a-/- mice. Altogether, our study provides evidence that miR-146a represses inflammation and diet-induced obesity and regulates metabolic processes at the cellular and organismal levels, demonstrating how the combination of diet and miRNA genetics influences obesity and diabetic phenotypes. Obesity and metabolic disease are on the rise throughout the world, creating a need for research into the interaction between diet and genetics. It is known that chronic inflammation contributes to obesity, but it is not well understood how inflammation and inflammatory genes are controlled to prevent obesity. Here we found that a specific microRNA, miR-146a, controls inflammation and prevents obesity onset when mice are fed a high-fat diet. In the absence of miR-146a, mice become obese and develop diabetic symptoms in a diet-dependent manner. We found that miR-146a is highly expressed in immune cells and regulates the inflammatory function of macrophages within fat tissue. Within macrophages, we identified metabolic pathways regulated by miR-146a that could contribute to its protective role during DIO, and show that blockade of mTOR using rapamycin could reverse the obesity phenotype in miR-146a-/- mice. Human studies have previously shown that miR-146a expression is decreased in obese and diabetic patients, and our work suggests that miR-146a is mechanistically involved in the development of obesity and therefore can be a potential therapeutic target. Taken together, our work demonstrates that miRNA genetics and lifestyle are both important, contributing factors to diet-induced metabolic disease.
- 15 February 2019
- Published by Public Library of Science (PLoS) in PLOS Genetics
- Vol. 15 (2) , e1007970
Open AccessAnti-inflammatory microRNA-146a protects mice from diet-induced metabolic disease
Identifying regulatory mechanisms that influence inflammation in metabolic tissues is critical for developing novel metabolic disease treatments. Here, we investigated the role of microRNA-146a (miR-146a) during diet-induced obesity in mice. miR-146a is reduced in obese and type 2 diabetic patients and our results reveal that miR-146a-/- mice fed a high-fat diet (HFD) have exaggerated weight gain, increased adiposity, hepatosteatosis, and dysregulated blood glucose levels compared to wild-type controls. Pro-inflammatory genes and NF-κB activation increase in miR-146a-/- mice, indicating a role for this miRNA in regulating inflammatory pathways. RNA-sequencing of adipose tissue macrophages demonstrated a role for miR-146a in regulating both inflammation and cellular metabolism, including the mTOR pathway, during obesity. Further, we demonstrate that miR-146a regulates inflammation, cellular respiration and glycolysis in macrophages through a mechanism involving its direct target Traf6. Finally, we found that administration of rapamycin, an inhibitor of mTOR, was able to rescue the obesity phenotype in miR-146a-/- mice. Altogether, our study provides evidence that miR-146a represses inflammation and diet-induced obesity and regulates metabolic processes at the cellular and organismal levels, demonstrating how the combination of diet and miRNA genetics influences obesity and diabetic phenotypes. Obesity and metabolic disease are on the rise throughout the world, creating a need for research into the interaction between diet and genetics. It is known that chronic inflammation contributes to obesity, but it is not well understood how inflammation and inflammatory genes are controlled to prevent obesity. Here we found that a specific microRNA, miR-146a, controls inflammation and prevents obesity onset when mice are fed a high-fat diet. In the absence of miR-146a, mice become obese and develop diabetic symptoms in a diet-dependent manner. We found that miR-146a is highly expressed in immune cells and regulates the inflammatory function of macrophages within fat tissue. Within macrophages, we identified metabolic pathways regulated by miR-146a that could contribute to its protective role during DIO, and show that blockade of mTOR using rapamycin could reverse the obesity phenotype in miR-146a-/- mice. Human studies have previously shown that miR-146a expression is decreased in obese and diabetic patients, and our work suggests that miR-146a is mechanistically involved in the development of obesity and therefore can be a potential therapeutic target. Taken together, our work demonstrates that miRNA genetics and lifestyle are both important, contributing factors to diet-induced metabolic disease.